JPS6134401B2 - - Google Patents
Info
- Publication number
- JPS6134401B2 JPS6134401B2 JP11668177A JP11668177A JPS6134401B2 JP S6134401 B2 JPS6134401 B2 JP S6134401B2 JP 11668177 A JP11668177 A JP 11668177A JP 11668177 A JP11668177 A JP 11668177A JP S6134401 B2 JPS6134401 B2 JP S6134401B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- capsule
- sustained
- release
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 33
- 239000002775 capsule Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 15
- 239000003302 ferromagnetic material Substances 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 9
- 239000012730 sustained-release form Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000005389 magnetism Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 239000000956 alloy Substances 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 235000013980 iron oxide Nutrition 0.000 claims description 3
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 230000005291 magnetic effect Effects 0.000 description 17
- 239000003405 delayed action preparation Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 239000000654 additive Substances 0.000 description 7
- 230000005294 ferromagnetic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011148 porous material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229910001030 Iron–nickel alloy Inorganic materials 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000859 α-Fe Inorganic materials 0.000 description 2
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- KCZFLPPCFOHPNI-UHFFFAOYSA-N alumane;iron Chemical compound [AlH3].[Fe] KCZFLPPCFOHPNI-UHFFFAOYSA-N 0.000 description 1
- 229910001566 austenite Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- -1 magnetite Chemical compound 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- HHAVHBDPWSUKHZ-UHFFFAOYSA-N propan-2-ol;propan-2-one Chemical compound CC(C)O.CC(C)=O HHAVHBDPWSUKHZ-UHFFFAOYSA-N 0.000 description 1
- 229910000702 sendust Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11668177A JPS5452719A (en) | 1977-09-30 | 1977-09-30 | Magnetizable slow release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11668177A JPS5452719A (en) | 1977-09-30 | 1977-09-30 | Magnetizable slow release preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5452719A JPS5452719A (en) | 1979-04-25 |
| JPS6134401B2 true JPS6134401B2 (de) | 1986-08-07 |
Family
ID=14693234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11668177A Granted JPS5452719A (en) | 1977-09-30 | 1977-09-30 | Magnetizable slow release preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5452719A (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0192601A (ja) * | 1987-10-05 | 1989-04-11 | Suganami Bussan Kk | 液晶表示式スケール |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3723310A1 (de) * | 1987-07-15 | 1989-01-26 | John Urquhart | Pharmazeutisches praeparat und verfahren zu seiner herstellung |
| DE4406139A1 (de) * | 1994-02-25 | 1995-08-31 | Matthias Werner | Magnetische Depotarzneimittel für die perorale Applikation mit verbesserter Resorption der Wirkstoffe |
| JP2006290821A (ja) * | 2005-04-13 | 2006-10-26 | Yoshiki Takeuchi | 小孔カプセル |
-
1977
- 1977-09-30 JP JP11668177A patent/JPS5452719A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0192601A (ja) * | 1987-10-05 | 1989-04-11 | Suganami Bussan Kk | 液晶表示式スケール |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5452719A (en) | 1979-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7455084B2 (ja) | 薬物透過性構成部材を備えた薬物送達デバイス、及び方法 | |
| US20260021224A1 (en) | Multi-Unit Drug Delivery Devices and Methods | |
| Jain et al. | Recent technologies in pulsatile drug delivery systems | |
| JP3176600B2 (ja) | 生物活性物質を運搬するための磁気応答組成物 | |
| DE69514192T2 (de) | Arzneimittel und/oder Nahrungsmikrokapseln zur oralen Verabreichung | |
| ES2867399T3 (es) | Dispositivo implantable con tolerabilidad intravesical | |
| US5445829A (en) | Extended release pharmaceutical formulations | |
| EP2793850B1 (de) | Detektionssystem zur erfassung magnetischer objekte im menschlichen organismus | |
| ES2170136T5 (es) | Formulaciones opioides para el tratamiento del dolor. | |
| US4747845A (en) | Synthetic resin matrix system for the extended delivery of drugs | |
| EP1155692B1 (de) | Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel | |
| JP2002528485A (ja) | 多粒子改質放出組成物 | |
| KR20010024836A (ko) | 자기 반응성 조성물 | |
| US20160279399A1 (en) | Osmotic drug delivery devices, kits, and methods | |
| DE69216910T2 (de) | Diltiazem enthaltende Zusammensetzung | |
| JPS626522B2 (de) | ||
| JPS6134401B2 (de) | ||
| JP4015184B2 (ja) | 疎水性剤を含有するディスペンサー | |
| JP2003512336A (ja) | 磁気標的化キャリア | |
| JPH0625055B2 (ja) | 持続性錠剤 | |
| MEYERS et al. | Pathologic studies following magnetic control of metallic iron particles in the lymphatic and vascular system of dogs as a contrast and isotopic agent | |
| Bchkol et al. | Review of the Controlled Drug Delivery Method, Dosage Form Categorization, and Therapeutic Impact on the Human Body | |
| DE4406139A1 (de) | Magnetische Depotarzneimittel für die perorale Applikation mit verbesserter Resorption der Wirkstoffe | |
| Jones et al. | Enhanced in vivo activity of adriamycin incorporated into controlled release microspheres | |
| Henderson | Recent Advances in Drug Delivery System Technology |